Autoimmunity

$4.7 Billion Autoimmune Diseases Diagnostics Global Market to 2026 - Technological Innovation in the Form of Lab Automation Presents Opportunities - ResearchAndMarkets.com

Wednesday, June 16, 2021 - 4:19pm

The "Global Autoimmune Diseases Diagnostics Market (2021-2026) by Product, Test Type, Disease, End-user, Geography and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Autoimmune Diseases Diagnostics Market (2021-2026) by Product, Test Type, Disease, End-user, Geography and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • An autoimmune disease is a disorder wherein one's immune system attacks the body and destroys its body tissue.
  • There have been around 80 different types of autoimmune disorders being identified, of which, multiple sclerosis, type 1 diabetes, rheumatoid arthritis are fairly common.
  • Factors such as a rise in the incidence of autoimmune diseases have been a major driver for the growth of the market of autoimmune drugs.

ChemoCentryx to Participate in the Raymond James 2021 Human Health Innovations Conference

Wednesday, June 16, 2021 - 1:30pm

SAN CARLOS, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Raymond James 2021 Human Health Innovations Conference on Wednesday, June 23 at 10:40 a.m.

Key Points: 
  • SAN CARLOS, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Raymond James 2021 Human Health Innovations Conference on Wednesday, June 23 at 10:40 a.m.
  • A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com.
  • ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer.
  • ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Global Autoimmune Disease Diagnostics Market 2021 to 2026 - Growth, Trends, COVID-19 Impact, and Forecasts - ResearchAndMarkets.com

Tuesday, June 15, 2021 - 3:36pm

The "Autoimmune Disease Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Autoimmune Disease Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The autoimmune disease diagnostics market is expected to register a CAGR of nearly 8.3% during the forecast period.
  • The other factors, such as improved laboratory automation, partnerships with physicians and clinical laboratories, and technological advancements, are driving the autoimmune disease diagnostics market.
  • However, the slow turnaround time of the diagnosis and high frequency of false results are hindering the growth of the autoimmune disease diagnostics market.

Virtis Health Expands Ambulatory Infusion Center Footprint and Infusion Management Services

Monday, June 14, 2021 - 1:00pm

Concurrently, the Company continues to expand its comprehensive infusion management and related physician practice management services nationwide.

Key Points: 
  • Concurrently, the Company continues to expand its comprehensive infusion management and related physician practice management services nationwide.
  • Virtis Health offers a range of therapy management services and treatments for patients with autoimmune disorders, including chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis and myasthenia gravis.
  • Virtis Healths Physician Services division provides comprehensive infusion center and practice management services to support physician and provider partners.
  • Additionally, the Company provides comprehensive infusion center and related practice management services to physicians, health systems and other medical entities nationwide.

Avidea's SNAPvax™ Tolerance Vaccine Program Boosted by SAB Appointments and Encouraging Preclinical Data

Monday, June 14, 2021 - 1:40pm

As members of the SAB, Jewell and Calabresi will advise Avidea's research and clinical development strategy, including Avidea's efforts to develop a tolerance vaccine for MS, referred to as SVT201.

Key Points: 
  • As members of the SAB, Jewell and Calabresi will advise Avidea's research and clinical development strategy, including Avidea's efforts to develop a tolerance vaccine for MS, referred to as SVT201.
  • "Avidea's tolerance vaccine ("SNAPvax TV") is optimized for priming regulatory T cell (Treg) responses against antigens implicated in autoimmune diseases.
  • Preclinical data show that SNAPvax TV primes Tregs and mitigates disease in a mouse model of MS referred to as EAE."
  • "The SAB appointments build upon our existing partnerships with UMD and NIH to significantly expand our capabilities in autoimmunity," said Lynn.

Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors

Thursday, June 10, 2021 - 1:00pm

Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it raised $107 million in a Series B financing.

Key Points: 
  • Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it raised $107 million in a Series B financing.
  • The companys platform also allows for the conjugation of its enhanced cytokines as payloads to certain antibodies, creating novel and proprietary Bright Peak Immunocytokines.
  • Also today, Bright Peak announced key additions to its board of directors with the appointments of independent directors Laura Shawver, Ph.D., and Christine Siu.
  • Bright Peak is also pioneering a new category of Bright Peak Immunocytokines that simultaneously leverages the precision of antibody targeting with cytokine-mediated selective immune modulation in the desired microenvironment.

The Lupus Release Alliance Awards 2021 Lupus Insight Prize to Immunologist Dr. Martin Kriegel

Wednesday, June 9, 2021 - 7:56pm

The prestigious Lupus Insight Prize recognizes outstanding researchers who have made a major discovery that promises to advance the understanding of lupus with a high likelihood of improving its diagnosis or treatment.

Key Points: 
  • The prestigious Lupus Insight Prize recognizes outstanding researchers who have made a major discovery that promises to advance the understanding of lupus with a high likelihood of improving its diagnosis or treatment.
  • Although existing research links alterations in the microbiome to autoimmunity, Dr. Kriegel is the first to identify a particular organism that breaks through the gut lining in lupus.
  • The Lupus Research Alliance is the largest non-governmental, non-profit funder of lupus research worldwide.
  • Because the Lupus Research Alliance's Board of Directors fund all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

SHAREHOLDER ALERT: Robbins LLP Reminds Investors that ChemoCentryx, Inc. (CCXI) is Being Sued for Misleading Shareholders

Wednesday, June 9, 2021 - 6:22pm

ChemoCentryx is a biopharmaceutical company that develops and commercializes new medications targeting inflammatory disorders, autoimmune diseases, and cancer.

Key Points: 
  • ChemoCentryx is a biopharmaceutical company that develops and commercializes new medications targeting inflammatory disorders, autoimmune diseases, and cancer.
  • ChemoCentryx's lead drug candidate is avacopan, which the Company describes as a "potential first-in-class, orally-administered molecule for the treatment of patients with ANCA vasculitis."
  • If you would like more information regarding your rights, please contact Lauren Levi at (800) 350-6003 or llevi@robbinsllp.com , or via our Shareholder Information Form .
  • Robbins LLP is a nationally recognized leader in shareholder rights law.

Equillium to Present at the JMP Securities Life Sciences Conference

Wednesday, June 9, 2021 - 1:00pm

LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities Life Sciences Conference, a virtual investor event, taking place June 16 and 17, 2021.

Key Points: 
  • LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities Life Sciences Conference, a virtual investor event, taking place June 16 and 17, 2021.
  • Bruce Steel, Equilliums chief executive officer, will provide a high-level overview of itolizumabs mechanism of action and review each of the ongoing clinical programs, with a focus on topline data from the companys EQUATE study in acute graft-versus-host disease, to be presented at EHA on Friday, June 11, 2021.
  • Mr. Steel and other members of Equilliums leadership team will be available for one-on-one meetings during the conference.

SQZ Biotechnologies Tolerizing Antigen Carrier (TAC) Program Induces Antigen-Specific Immune Tolerance in Preclinical Models Demonstrating Potential for Broad Applicability Across Autoimmune Diseases

Wednesday, June 9, 2021 - 11:45am

In models of Type 1 diabetes (T1D), SQZ TACs were able to delete antigen-specific T cells, without causing non-specific immune suppression, ultimately preventing hyperglycemia.

Key Points: 
  • In models of Type 1 diabetes (T1D), SQZ TACs were able to delete antigen-specific T cells, without causing non-specific immune suppression, ultimately preventing hyperglycemia.
  • Together, these results suggest that SQZ TACs are a versatile platform for inducing antigen-specific immune tolerance.
  • The holy grail for effectively treating autoimmune diseases is the ability to precisely target autoreactive T cells without inducing broad immunosuppression, said Howard Bernstein, M.D., Ph.D., chief scientific officer at SQZ Biotechnologies.
  • SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases.